Rallybio Declares $82.7M Special Cash Distribution To Stockholders And Pre-Funded Warrant Holders, Estimated At $13.56/Share, In Connection With Avenzo Therapeutics Merger
As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") with
Share
Why It Matters
Rallybio is paying shareholders $13.56 per share from a merger. This means the company is returning cash to people who own its stock.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.